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Abstract
Background: The objective of this study was to compare 
functional and surgical outcomes of patients undergoing il-
eocecal resection for Crohn’s disease (CD) to patients under-
going oncological right colectomy. Methods: Retrospective 
single-center cohort study including consecutive patients 
undergoing right colectomy for adenocarcinoma (oncologi-
cal resection) or CD (mesentery-sparing resection) between 
July 2011 and November 2017. Outcome measures were 
pathological details (lymph node yield), postoperative re-
covery (pain levels, return to flatus and stool, intake of fluids, 
weight change, and mobilization), and early (30-day) out-
comes (surgical/medical complications, hospital stay, read-
missions). Results: A total of 195 patients (153 [78%] with 
cancer and 42 [22%] with CD) were included. Overall compli-
ance with the institutional enhanced recovery protocol was 
comparable between the 2 groups (compliance ≥70%: 60% 
in CD patients vs. 62% in cancer, p = 0.458). The adenocarci-
noma group had a larger lymph node yield than the CD 
group (26 ± 13 vs. 2.4 ± 5, respectively, p < 0.001). While the 
CD group experienced significantly more pain (3.7 ± 1.9/10 
vs. 2.8 ± 2.5/10, p = 0.007, patients requiring opioids: 65 vs. 
28%, p = 0.001), return of flatus (2.3 ± 1.2 days vs. 2.4 ± 2.8 
days, p = 0.642) and stool (4.1 ± 6.0 vs. 3.0 ± 1.8 days, p = 
0.292) was no different in both groups. No difference was 
observed regarding postoperative complications, length of 
stay, and readmission rate. Conclusion: This study revealed 
no differences in both functional and surgical outcomes in 
CD and cancer patients undergoing mesentery-sparing or 
formal oncological right colectomy, respectively.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Crohn’s disease (CD) is an immune-mediated chron-
ic disease that can affect any segment of the digestive 
tract and features transmural invasion and fistula for-
mation [1]. Despite being a non-curative disease, more 
than half of patients need surgical treatment for medi-
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cally refractory inflammation leading to acute (i.e., per-
foration) or chronic (i.e., stricture) complications [2]. 
With 58%, the ileocecal segment is the most prevalent 
primary location of the disease and may require ileoce-
cal resection for disease control [3, 4]. Formal right col-
ectomy is the standard approach to right-sided colon 
cancer, in which a central resection with high ligation of 
the ileocolic axis is mandatory for complete removal of 
tumor-draining lymphovascular tissue. Conversely, CD 
typically needs less radical resection of lymphovascular 
structures and is mainly guided by the extent of the in-
flammatory process.
Because the Abbreviated Injury Scale for mesenteric 
injury in traumatology reflect a supposed increased risk 
of small bowel obstruction, central resection of the ileo-
colic pedicle and its neurovascular structures may have 
a negative impact on recovery of bowel function [5, 6]. 
On the other hand, wide mesentery-including resections 
have been suggested in patients with CD for better con-
trol of disease recurrence [7–9]. The objective of this 
study was to compare functional recovery and surgical 
outcomes in patients undergoing mesentery-sparing il-
eocecal resection for CD to patients undergoing onco-
logical right colectomy to explore whether wider mesen-
teric resections in CD may harm patient outcome.
Methods
This is a retrospective cohort study with data deriving from 
the enhanced recovery after surgery (ERAS) database of the De-
partment of Visceral Surgery at Lausanne University Hospital 
(CHUV). Consecutive patients undergoing right colectomy or 
ileocecal resection for either primary, histology-proven stage 
I–III adenocarcinoma, or CD with an established preoperative 
diagnosis between July 2011 and November 2017 were included.
Demographic information included age, gender, American 
Society of Anesthesiologists (ASA) and World Health Organiza-
tion (WHO) mobility performance scores (WHO 0: fully active, 
able to carry on all pre-disease performance without restriction-
WHO 5: dead), BMI, social habits including active smoking and 
alcohol abuse (as defined by Diagnostic and Statistical Manual of 
Mental Disorders [DSM-5] coding) at the time of surgery, im-
munosuppressive medications (i.e., chemotherapy or steroids 
within 12 weeks of surgery), previous history of abdominal sur-
gery, and postoperative nausea or vomiting. Surgical information 
included surgical approach (either open or minimally invasive, 
including preemptive or reactive conversion to laparotomy), 
elective or emergency (within 72 h of unplanned admission) in-
dication, length of the operation (from anesthesia induction un-
til skin closure), and length of the incision (<10 vs. >10 cm).
For CD patients, a bowel-close resection was performed. All 
cancer patients underwent a radical D2-lymphadenectomy yield-
ing proximal and distal resection margins of at least 5 cm. Com-
plete mesocolic excision preserving the mesocolic plane and cen-
tral ligation of the ileocolic vessels at their origin were performed 
routinely [10]. Anastomoses in both groups were performed in a 
standardized side-to-side anisoperistaltic stapling technique or 
an isoperistaltic side-to-side hand-sewn technique.
The institutional ERAS protocol has been previously de-
scribed [11]. Compliance to individual ERAS items was calcu-
lated using the previously described critical cutoff of 70% (overall 
compliance) for comparative purposes [12].
Outcomes
Functional outcomes included postoperative pain levels, as-
sessed by visual analog scales (VAS 0: no pain 10: highest pain 
intensity) and opioid use at postoperative day (POD) 0–3 for ad-
equate pain control, time from surgery to return to flatus and 
stool, postoperative oral intake of fluids (L/24 h), postoperative 
weight change (POD 1–3 compared to preoperative weight), and 
postoperative mobilization (hours/day, POD 1–3). Postoperative 
complications were assessed according to the Clavien classifica-
tion [13] (with major complications defined as ≥grade III) and 
included infectious (surgical site infection and medical infectious 
including urinary tract infection and pneumonia), respiratory 
(atelectasis) and cardiovascular complications (arrhythmias, 
deep venous thrombosis, pulmonary embolism), urinary reten-
tion (need for in/out catheterization), anastomotic leakage (clin-
ically or radiologically confirmed), postoperative length of stay 
(surgery to discharge), readmission (to either index or indepen-
dent facility), and postoperative ileus (POI) or small bowel ob-
struction. POI was defined as postoperative reinsertion of a na-
sogastric tube after removal at the end of anesthesia. Small bow-
el obstruction was defined as the need of reoperation. For the 
purpose of this study, both entities were combined.
Specific Assessments for Oncological and Crohn’s Patients
For oncological patients, distal, proximal, and vascular pedi-
cle tumor resection margins and total, peritumoral, and central 
lymph nodes were reviewed by specialized institutional patholo-
gists [14]. For CD patients, preoperative medical therapy in-
cluding corticosteroids, immunomodulators (azathioprine and 
methotrexate), and biologic molecules (adalimumab, certoli-
zumab, infliximab, vedolizumab, and ustekinumab), which were 
stopped at minimal drug half-life time (at least 10–25 days), ex-
cept for emergency surgical indications, were analyzed. Surgical 
indication (medically refractory or complicated disease: stenosis, 
fistula, and perforation), need of oncological resection (high-tie 
of the ileocolic axis), and total number of resected lymph nodes 
were also assessed.
Statistical Analysis
Descriptive statistics were reported as frequency and percent-
ages and continuous variables were reported as mean (SD) or 
median (interquartile range-IQR). χ2 test was used for categorical 
variables and Student’s t test for continuous variables. Variables 
with a p value <0.05 indicate statistical significance. Statistical 
analyses were performed with the Statistical Software for the So-
cial Sciences SPSS Advanced Statistics 22 (IBM Software Group, 
200 W. Madison St., Chicago, IL 60606, USA) and GraphPad 







A total of 195 patients (153 [78%] with cancer and 42 
[22%] with CD) were included. Oncological patients were 
older, sicker (ASA score), and had higher BMI scores, as 
outlined in Table 1. There were no differences in social 
habits, WHO performance scores, and previous surgery 
or postoperative nausea or vomiting history between 
both groups. While CD patients were more often oper-
ated by minimally invasive approach (90 vs. 76%, p = 
0.053), the conversion rate (all pre-emptive) was compa-
rable. Most anastomoses (n = 172, 88%) were configured 
in an anisoperistaltic stapled fashion with equal distribu-
tion between both groups.
Compliance with the Enhanced Recovery Protocol
Overall compliance with the ERAS protocol was simi-
lar between the 2 groups (≥70%: 62% in cancer vs. 60% in 
CD patients, p = 0.458). Significant differences were ob-
served in intraoperative EDA use and postoperative opi-
oid use within 48 h (see online suppl. material; see www.
karger.com/doi/10.1159/000509748 for all online suppl. 
material). Further specifics of CD and cancer patients re-
garding preoperative immunosuppressive treatments 
and pathological details are summarized in Tables 2 and 
3. The adenocarcinoma group had a larger lymph node 
yield than the CD group (26 ± 13 vs. 2.4 ± 5 respectively, 
p < 0.001).
Functional Outcome
Return of flatus was 2.3 ± 1.2 days in CD versus 2.4 ± 
2.8 days in cancer patients, p = 0.642, while return of stool 
was 4.1 ± 6.0 days in CD versus 3.0 ± 1.8 days in cancer 
patients. The CD group experienced significantly more 
pain at POD 0, POD 1, POD 2, and POD 3, as shown by 
both increased VAS scores and increased use of opioid 
medication through POD 3 (Fig. 1). Oncological patients 
gained significantly more weight (POD 2 and 3), while no 
differences in postoperative mobilization and oral intake 
were observed.
Surgical Outcome
Infectious, cardiovascular, respiratory, abdominal, 
urinary, and anastomotic complication rates were similar 
in both groups (Table 4). No difference was observed for 
length of stay and readmission rate.
Table 1. Demographics and surgical details







Age (mean ± SD), years 64±20 37±15 71±14 <0.001
>70 years, n (%) 97 (50) 1 (2) 96 (63) <0.001
Gender (male), n (%) 100 (51) 24 (57) 76 (50) 0.486
ASA group (III–IV), n (%) 65 (33) 3 (7) 62 (41) <0.001
WHO performance score (≥2), n (%) 45 (23) 7 (17) 38 (25) 0.306
BMI (mean±SD), kg/m2 25±6 23±5 26±6 0.001
>25 kg/m2, n (%) 85 (44) 12 (29) 73 (48) 0.035
Smoker, n (%) 40 (21) 13 (31) 27 (18) 0.083
Alcohol, n (%) 15/155 (10) 14/120 (12) 1/35 (3) 0.193
Immunosuppression, n (%) 41 (21) 33 (79) 8 (5) <0.001
Previous abdominal surgery, n (%) 54 (28) 8 (19) 46 (30) 0.177
Previous PONV, n (%) 14/189 (7) 4 (10) 10/147 (7) 0.517
Minimally invasive approach, n (%) 155 (79) 38 (90) 117 (76) 0.053
Conversion, n (%) 7/155 (5) 2/38 (5) 5/117 (5) 0.683
Emergency indication, n (%) 49 (25) 7 (17) 42 (27) 0.167
Duration of operation (mean±SD), min 150±70 140±60 150±70 0.194
>180 min, n (%) 55 (28) 10 (24) 45 (29) 0.564
Hand-sewn anastomosis, n (%) 23 (12) 4 (10) 19 (12) 0.789
Incision > 10 cm, n (%) 75/189 (40) 10/41 (24) 65 (44) 0.030
All conversions from laparoscopy to laparotomy were done preemptively. Baseline demographic parameters 
of patients with CD (n = 42) and patients with adenocarcinoma (n = 153) undergoing ileocecal resection or right 
colectomy. Bold p values indicate statistical significance (p < 0.05). CD, Crohn’s disease; ASA, American Society 
of Anesthesiology; WHO, World Health Organization erformance score; PONV, postoperative nausea and vom-
iting; SD, standard deviation.





Despite more central resection and as expected in-
creased lymph node yield in cancer patients and similar 
compliance to the perioperative care protocol, recovery 
of bowel function did not differ between both groups. 
While CD patients experienced more postoperative pain, 
no differences were observed in postoperative complica-
tions, length of stay, and readmissions. Based on these 
data, more extensive resection in CD patients to prevent 
disease recurrence may be warranted and will most likely 
not negatively impact functional recovery.
Surgery is obviously not a curative treatment for CD. 
Endoscopic recurrence occurs in 30% at 1 year and 85% 
at 3 years after surgery, while clinical recurrence at 1 year 
occurs in 8–20% [15–17]. Furthermore, surgical recur-
rence occurs in 30% of patients at 10 years [18, 19]. High 
visceral fat area and high mesenteric fat index are associ-
ated with postoperative recurrence at 6 months [20]. Cof-
fey et al. [8] evaluated the rate of surgical recurrence be-
tween conventional, mesentery-sparing ileocolic resec-
tions for CD and those including a wide mesenteric 
resection and demonstrated that retention of the mesen-
tery was an independent predictor of surgical recurrence. 
In their study, the rate of surgical recurrence was 40% 
after conventional ileocolic resection against 2.9% with 
wide excision of the mesentery. Therefore, mesenteric re-
section was suggested as an efficient technique to de-
crease postoperative recurrence since widespread resec-
tion was linked to a higher lymph node yield and thus 
reduction of potential immunologic reactions. The au-
thors also explained the beneficial effect of mesenteric re-
section by assuming that it reduces the local recruitment 
of fibrocytes. The percentage of fibrocytes correlated with 
the mesenteric disease severity, which in turn correlated 
to the CD activity index and the mucosal disease activity 
index. Furthermore, mesenteric resection was associated 
with reduced intestinal resection and margin positivity 
rate.
However, the role of mesentery in CD is still matter of 
debate, as some authors suggested an immunological 
protection of fat wrapping [21, 22]. According to their 
data, radical mesenteric resection could lead to poorer 
clinical outcomes. Furthermore, resection of the mesen-
tery is associated with a non-negligible risk of bleeding, 
which can cause major peri- and postoperative complica-
tions [9]. In the present study, mesenteric resection did 
not lead to increased overall or specific postoperative 
complications. For this reason, the results may support a 
more extended surgical approach in CD. However, 
whether the mesentery has an immunological protection 
or not, in ileocecal CD, needs to be determined by further 
studies.
Table 3. Specifics adenocarcinoma patients












R0 resection, n (%) 152 (99)
Pathologic details of patients with adenocarcinoma (n = 153). 
SD, standard deviation.















Medically refractory 8 (19)
Stenosing disease 36 (86)
Fistulizing disease 7 (17)
Perforating disease 2 (5)
Pathologic details
Oncologic resection 0
Total lymph nodes (mean±SD) 2.4±5
Preoperative treatments, surgical indications, and pathologic 
specifics of Crohn’s patients (n = 42). AZA, azathioprine; MTX, 
methotrexate; ADA, adalimumab; CTZ, certolizumab; IFX, inflix-






Mascarenhas et al. [23] analyzed short-term outcomes 
after ileocolic resection and right hemicolectomies for 
CD patients compared with non-Crohn’s comparative 
group and showed no differences in postoperative needs 
for surgical re-intervention and POI. They concluded 
that the underlying pathology does not influence surgical 
outcomes, similar as the present study, which focused in 
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Fig. 1. Functional outcome, postoperative pain, oral intake and 
weight, and mobilization. Comparison of postoperative pain 
scores (left) and percentage of patients needing opioid medication 
(right) (a), oral fluid intake (left) and weight change (right) (b), 
and mobilization of patients with CD (n = 42, blue lines) (c) and 
patients with adenocarcinoma (n = 153, red lines). CD, Crohn’s 
disease; VAS, visual analog scale; POD, postoperative day; SEM, 
standard error of the mean. * Indicates statistical significance (p < 
0.05). Displayed are means (squares) with SEM.




ies revealed delayed GI function associated with colecto-
my for inflammatory bowel disease [24, 25]. Dai et al. [24] 
suggested preoperative conditioning (normalization of 
albumin levels, steroid weaning) and early management 
of postoperative sepsis as efficient measures to reduce 
POI.
In the present analysis, CD patients, who were young-
er than the comparative cancer group, experienced sig-
nificantly more postoperative pain. Preoperative chron-
ic pain and young age have been repeatedly identified as 
risk factors for increased postoperative pain [26, 27]. Ar-
guably, chronic abdominal pain is a major concern in 
CD patients [3]. While preoperative pain intensity was 
not assessed in the present study, both subjective (VAS 
scores) and objective (opioid consumption) measures 
were used to evaluate postoperative pain. Reasons for 
higher postoperative pain scores are multifold and may 
also depend on pain assessment, according to Gagliese 
et al. [28] who showed that VASs were not sensitive 
enough to detect age differences compared to other in-
struments. However, our assessment also revealed sig-
nificant differences in opioid requirements in the young-
er CD cohort.
This present study showed further increased weight 
gain in oncological patients, potentially due to less water 
retention in younger patients as a result of decreased in-
traoperative IV fluid administration, increased postop-
erative ambulation, and better general capacity to elimi-
nate excess fluids in the younger CD cohort. Interesting-
ly, ERAS compliance overall did not differ between both 
groups, further supporting feasibility of ERAS care in all 
age-groups [29].
This study has several limitations related to the retro-
spective study design. The modest sample size impeded 
case matching to account for the heterogeneity of the 
comparative cohorts and is based on a single-center ex-
perience, which, however, allowed comparison within 
highly standardized perioperative and surgical care. Thus, 
our results need independent confirmation by adequate-
ly powered prospective studies comparing extended and 
non-extended resection, ideally solely in CD patients in a 
randomized fashion. Opioid consumption was not asso-
ciated with poorer functional outcome. However, the 
dosage was not specified. Long-term results were not yet 
available in this study but are needed to assess the true 
impact of extended resection on CD recurrence. In con-
clusion, this study revealed no differences in both func-
tional and surgical outcome in CD and cancer patients 
undergoing mesentery sparing or formal oncological 
right colectomy, respectively.
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Table 4. Surgical outcome







Any complication, n (%) 87 (45) 20 (48) 67 (44) 0.727
Major complication (Clavien ≥ III), n (%) 16 (8) 2 (5) 14 (9) 0.530
Infectious complication, n (%) 31 (16) 6 (14) 25 (16) 1.000
POI/SBO, n (%) 34 (17) 8 (19) 26 (17) 0.756
Respiratory complication, n (%) 16 (8) 1 (2) 15 (10) 0.201
Cardiovascular complication, n (%) 6 (3) 0 6 (4) 0.334
UTI, n (%) 6 (3) 0 6 (4) 0.344
Urinary retention, n (%) 13 (7) 4 (10) 9 (6) 0.483
Anastomotic leak, n (%) 4 (2) 1 (2) 3 (2) 0.512
LoS, days (median, IQR) 5 (3, 8) 5 (3, 7) 6 (3, 8) 0.087
Readmission, n (%) 16/190 (8) 3/40 (8) 13/150 (8) 1.000
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